Development of L-745,870, a selective D4 receptor antagonist, for the treatment of levodopa-induced dyskinesia
Toronto Western Hospital
Levodopa-induced dyskinesia remains one of the major factors limiting the usefulness of current treatments for Parkinson’s disease. The program has potential to provide a pharmacological means to reduce the impact of dyskinesia on the quality of life of people with PD. If successful the program will define safety and appropriate doses of L-745,870. It will demonstrate the ability of L-745,870 to reduce Levodopa-induced dyskinesia in a small, well-controlled clinical trial in patients with PD. We will thus provide a drug product that can be further assessed for safety.